On May 18, 2020, BioSig Technologies and its subsidiary, ViralClear Pharmaceuticals, announced the U.S. Food and Drug Administration (FDA) has completed its review of ViralClear’s Investigational New Drug application.

The FDA informed ViralClear that it may proceed with a proposed phase II study of merimepodib oral solution in adults with COVID-19 who are hospitalized and either require supplemental oxygen or are on non-invasive ventilation or high flow oxygen devices.